Clinical trial
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and…
NCT00102505 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00102505 |
|---|---|
| Title | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium Injection |
| Enrollment | 36 |
| Start date | Nov 1, 2004 |
| First posted | Jan 31, 2005 |
| Last update posted | Apr 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: